Correlation of Midkine Serum Level with Pro- and Anti-Inflamatory Cytokines in Multiple Sclerosis by Shaygannejad, Vahid. et al.
Iran.J.Immunol. VOL.11 NO.2 June 2014                                                                                134 
SHORT PAPER 
 
Correlation of Midkine Serum Level with 
Pro- and Anti-Inflamatory Cytokines in 
Multiple Sclerosis  
 
 
Vahid Shaygannejad1, Saeed Montazeri2, Azam Jamshidian3, Soheil Tahani1,5, 
Marjan Gharagozloo4, Fereshteh Ashtari1, Sahar Vesal1, Seyed Javad 
Hasheminia5, Leila Dehghani1,5* 
 
1
Department of Neurology and Isfahan Neurosciences Research Center, 
2
Medical Student Research 
Center, Isfahan University of Medical Sciences, Isfahan, 
3Immunology and Microbiology Department, 
Faculty of Medicine, Shahrekord University of Medical Sciences, Shahrekord, 
4
Department of Immunology, 
School of Medicine, Isfahan University of Medical Sciences,
 5 Department of Medical Sciences, Najafabad 
Branch, Islamic Azad University, Isfahan, Iran 
 
 
ABSTRACT 
 
Background: Midkine (MK) is a heparin-binding growth factor with promoting effects 
in inflammatory responses through enhancing leukocytes migration. Objective: To 
study the correlation between MK serum levels and concentration of inflammatory 
cytokines in Multiple Sclerosis (MS) patients. Methods: We evaluated the MK level 
and its relationship with inflammatory cytokines (IL-17 and IL-23) and anti-
inflammatory ones (IL-10 and TGF-β) in multiple sclerosis (MS) patients. The serum 
concentrations of MK and cytokines were assessed by ELISA in 32 MS patients in 
comparison with 32 healthy subjects. Results: Our data showed that the MK 
concentration in MS patients is lower than healthy controls (341.15 ± 40.71 Pg/ml vs. 
620.15 ± 98.61 Pg/ml, respectively, p=0.015). We also observed a significant decrease 
in IL-10, IL-23, and TGF-β cytokine levels in MS patients. There was a significant 
correlation between MK and IL-23 concentrations in our study (r = +0.829, p≤ 0.001). 
Conclusion: These results confirm a role for MK in inflammatory reactions in MS.  
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INTRODUCTION 
 
Multiple sclerosis (MS) is an autoimmune-mediated disease of the central nervous 
system (CNS) that occurs in genetically susceptible individuals (1). Numerous potential 
biomarkers have been considered for determining the trend of illness and also for 
response to the treatment of MS, but their clinical success has not yet been fully 
confirmed (2). 
Midkine (MK) is a heparin-binding growth factor with various effects in different 
tissues of the body, including an important role in induction of oncogenesis, 
inflammation and restoration of tissues. MK induces inflammation via increasing 
leukocytes migration, induction of chemokine synthesis and preventing development of 
regulatory T cells (3). An important role for MK in inducing experimental autoimmune 
encephalitis (EAE) has been confirmed by disease attenuation in Mk deficient animals 
due to increasing regulatory T-cell (Treg) population in peripheral lymphatic glands, also 
reducing activated T helper type 1 (Th1) and Th17 cell populations in these animal 
models (4). 
Th17cells are a subset of CD4+ T cells with the ability of secreting inflammatory 
cytokines of IL-17 family and play a critical role in development of inflammatory 
responses (5). They have been shown to be the most important subset of T helper cells 
in pathogenesis of MS and EAE (4,6). In vitro studies suggest that IL-23 may provide a 
survival signal for already differentiated Th17 cells (1,5). 
Another subset of CD4+ T cells namedregulatory T cells (Treg), are considered to have a 
prominent role in controlling MS disease promotion, mainly through secreting anti-
inflammatory cytokines such as IL10 and TGF-β (7). Onset of several autoimmune 
diseases is associated with lack of TGF-β1 expression or defect in signaling pathways in 
T cells related to this cytokine (7,8). Moreover, TGF-β has an important role in inducing 
regulatory phenotype and their differentiation to Treg cells (4).  
MK has been suggested to be used as a disease prognosis predictor of cardiac events in 
patients with chronic heart failure (9). Also a significant relationship between MK 
serum levels and EAE severity has been reported in animal studies (4,10,11), while such 
relation has not yet been studied in human subjects. The present study was designed to 
measure the serum MK levels and correlate it with the above mentioned Th17 and Treg 
related inflammatory and anti-inflammatory cytokines in MS patients. Present research 
aimed to address correlation between MK serum level and concentration of anti-
inflammatory and inflammatory cytokines in MS patients. 
 
 
MATERIALS AND METHODS 
 
Human Subjects. Plasma samples were collected from 32 MS patients attending to 
neurology ward, Isfahan Kashani Hospital, Iran, between 2012-2013 which were kept at 
-80C, and 32 age- and sex-matched healthy controls. All patients were definitely 
diagnosed with MS disease according to the McDonald criteria. The study was 
approved by the Ethics Committee of Isfahan University of Medical Sciences and all 
subjects signed an informed consent. 32 MS patients were included in this study of 
which 19 (59.4%) had relapsing remitting (RRMS), 11 (34.4%) had secondary 
progressive (SPMS) and 2 (6.2%) had primary progressive (PPMS) MS. The mean 
disease duration was 4.68 ± 3.81 years and the average EDSS (Expanded Disability 
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Status Scale) score at the time of sampling was 3.2 ± 2.09. The sampling among RRMS 
patients was performed in relapse phase.The mean age in MS and control groups was 
32.4 ± 5.6 and 31.8 ± 4.3 years, respectively. All patients were under treatment with 
Interferon-β except primary progressive patients.   
Cytokine levels were evaluated by enzyme linked immunosorbent assay (ELISA) 
method using MK and IL-23 assay kits (Glory Science, USA), and IL-10 , IL-17 and 
TGF-β assay kits (Boster, wuhan, china). Selected wave length to read the ELISA plates 
and measure the absorbances was 490 nm. 
Statistical Analyses. The data were expressed as mean ± SEM (standard error of the 
mean). Student’s t-test, ANOVA and Tukey’s post hoc test were used where needed. 
Spearman correlation test was used to investigate the relationship between MK and 
other cytokine levels and disease severity and progression. p<0.05 was considered 
statistically significant. Data were analyzed by SPSS software 18.00. 
 
 
RESULTS 
 
MK levels in MS patients was significantly lower than healthy controls (341.15 ± 40.71 
pg/ml vs. 620.15 ± 98.61 pg/ml, respectively, p=0.015). Plasma levels of IL-10, TGF-β 
and IL-23 were also significantly decreased in MS patients (64.34 ± 15.56, 976.46 ± 
132 and 144 ± 19.31 pg/ml, respectively) compared to healthy controls (615.93 ± 49.13, 
1659.43 ± 258 and 212.65 ± 31.72 pg/ml, p=0.001, p=0.02 and p=0.04, respectively, 
Figure 1). However, elevation of IL-17 (18.65 ± 1.2 pg/ml) in plasma of MS patients in 
comparison with healthy controls (17.53 ± 3.71 pg/ml) was not significant (Figure 1). 
Among all cytokine/chemokine and clinical parameters analyzed in the relapse phase 
the only observed significant relationship was a positive correlation between plasma 
levels of IL-23 and MK (r = +0.829, p≤ 0.001). There was no correlation between 
plasma level of MK and MS severity or disease type. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1. Comparison of serum cytokine levels between healthy controls and MS patients.  
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DISCUSSION 
 
Different types of immune cells and soluble mediators contribute to the complex 
mechanism underlying the onset and progression of MS, which is characterized by 
infiltration of auto-reactive T cells and activation of microglia, in the CNS (3,5,8). MK 
promotes inflammatory responses by enhancing the migration of inflammatory 
leukocytes (11-13), increasing chemokine synthesis (13), and suppressing regulatory T 
cells induction (4). However, the precise immunological function of MK remains to be 
elucidated. The critical role of Th17 cells in development of auto-immune disorders like 
MS has been revealed in recent years (14). It is supposed that IL-23 is an essential 
cytokine in expansion and survival of Th17 population (15). 
Increased levels of MK in plasma of patients during inflammatory diseases such as 
Alzheimer’s disease (16) and rheumatoid arthritis (17), also in animals with EAE (4) 
have been shown in previous reports. In the present study, we assessed plasma levels of 
this protein in MS patients in relapse phase in comparison with healthy subjects and 
explored its possible relation with the concentration of other mentioned cytokines and 
also the disease clinical parameters. Our results indicated a decreased MK level in MS 
patients compared with healthy controls. This is in controversy with the results of 
animal studies which have shown MK elevation in MS experimental models (4). The 
same discrepancy was also seen in comparison of IL-23 and IL-17 levels in MS patients 
with Healthy subjects. These inconsistencies may be due to the effects of IFN-β 
treatment in studied patients. Accordingly, several studies have demonstrated that IFN-β 
may exert its effects on MS by reduction of IL-17-associated immunity (18,19). A study 
has reported that administration of IFN-β decreases IL-23 production and its decrease 
could be responsible for indirect inhibition of Th17 (18).  
The loss of Treg cell function which are the main producers of anti-inflammatory 
cytokines, TGF-β and IL-10, gives rise to various autoimmune diseases including MS 
(19-24). Our results showing a decrease in concentrations of both TGF-β and IL-10 
cytokines in MS patients is in agreement with the previous reports. 
A considerable result of the present study was the observed significant direct correlation 
between MK and IL-23 levels. This observation strongly confirms the inflammatory 
effects of MK and it suggest that the MK inflammatory functions may be exerted by 
mediating some influences on the production of IL-23 which indeed acts as the main 
cytokine in promoting the expansion and the survival of Th17 cells (25,26).  
In conclusion our results suggest that midkine can play an indirect role in promotion of 
inflammatory reactions in MS disease. Also it should be considered that IFN-β therapy 
may exert its alleviating effect through decreasing MK production. More detailed 
studies in this regard are needed.  
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